Thymalfasin (Thymosin Alpha-1) for Chronic Hepatitis B: A Comprehensive Drug Review | Research

The takeaway

Thymalfasin (thymosin alpha-1) showed sustained virological response rates of 25-40% as monotherapy for chronic hepatitis B, with superior durability compared to interferon and a much better safety profile.

Responses improve over time
Unlike interferon where responders can relapse, thymalfasin responses INCREASE over extended follow-up — suggesting durable immune reconversion

What the researchers found

Thymalfasin achieved 25-40% sustained virological response in chronic HBV with response rates increasing over follow-up (unlike interferon relapse), superior safety profile, and durable immune-mediated viral control.

Why it matters

Chronic HBV affects 300 million people. A well-tolerated drug with durable responses that improve over time addresses the biggest limitation of existing therapies — treatment durability.

How the study worked

Comprehensive drug review covering thymalfasin mechanism (T-cell, NK, DC activation), clinical trial data (monotherapy and combinations), sustained response rates, and safety profile.

What this study cannot tell us

Review of available trial data through 2004. Some trials had small sample sizes. The mechanism of increasing response over time was not fully explained.

How to read the evidence

Moderate evidence from a comprehensive review of multiple clinical trials with consistent response and safety data.

When this study was published

Published in 2004. Thymalfasin is approved in 30+ countries for HBV and continues to be studied in combination with antivirals.

The bigger picture

Thymalfasin's increasing response over time suggests it induces true immune reconversion — the immune system learning to permanently control HBV — rather than just temporary suppression.

Questions still open

Could thymalfasin achieve functional HBV cure?
Should it be first-line therapy for chronic HBV?
Does combining with nucleos(t)ide analogs improve response further?

Common questions

Is thymosin alpha-1 effective for hepatitis B?

Yes — it achieves 25-40% sustained viral response as monotherapy, with the unique advantage that response rates improve over time as the immune system learns to control the virus.

Is it better than interferon?

Similar cure rates but much better tolerated — far fewer side effects. And unlike interferon where some responders relapse, thymalfasin responses tend to increase over time.

Read the original research

Thymalfasin for the treatment of chronic hepatitis B.

Expert review of anti-infective therapy, 2(1), 9-16

View on PubMed ↗

Citation

Chien, Rong-Nan; Liaw, Yun-Fan. (2004). Thymalfasin for the treatment of chronic hepatitis B.. Expert review of anti-infective therapy, 2(1), 9-16.